Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study
Therapeutic Advances in Musculoskeletal Disease · 2026-08 · 18
DOI: 10.1177/1759720x261477844 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 17.08.2026. Verfasst von Mengmeng Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, The Third People 's Hospital Health Care Group of Cixi, Ningbo, Zhengjiang, China. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Postmenopausal rheumatoid arthritis (RA) patients receiving oral glucocorticoids (GCs) are at markedly increased risk for osteoporosis and fractures. Direct comparisons between denosumab and alendronate in this high-risk subgroup remain limited.
Objectives
To evaluate denosumab versus alendronate regarding one-year incidence of fragility fractures, bone mineral density (BMD) changes, bone turnover markers, and disease activity in postmenopausal RA patients on long-term oral GCs.
Design
Retrospective multi-center propensity score-matched cohort study.
Methods
From January 2018 to December 2023, 295 patients (122 denosumab, 173 alendronate) were enrolled. Propensity score matching (1:1) balanced 22 baseline covariates, yielding 124 patients (62 per arm). Outcomes included new fragility fractures, BMD alterations (including areal BMD (aBMD)), serum procollagen type I N-terminal propeptide (P1NP) and C-terminal telopeptide of type I collagen (CTx) levels, and disease activity scores over one year.
Results
Denosumab produced a significantly greater lumbar spine aBMD gain than alendronate (between-group difference: 0.444%, P=0.025). The absolute risk difference for fragility fracture with denosumab versus alendronate was 3.2% (95% CI: -2.2% to 8.6%), corresponding to fracture rates of 8.1% vs. 1.6% (OR=5.35, 95% CI: 0.59–48.68, P=0.135). Sensitivity analyses suggested a potential trend of elevated risk, but the very low number of fracture events (n=6) precludes definitive conclusions. No significant differences were observed for other BMD sites, bone turnover markers, or disease activity.
Conclusion
In postmenopausal RA patients on GCs, denosumab was superior to alendronate for lumbar spine BMD gains. The absolute risk difference for fragility fracture with denosumab versus alendronate was 3.2% (95% CI: -2.2% to 8.6%), but this finding remains inconclusive due to insufficient power and rare events. Larger prospective studies are needed to clarify fracture outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, The Third People 's Hospital Health Care Group of Cixi, Ningbo, Zhengjiang, China.
- Ningbo Women and Children's Hospital, The Women and Children's Hospital of Ningbo University, Ningbo, Zhengjiang, China.
- Department of Orthopedic Trauma, Beijing Jishuitan Hospital, Capital Medical University, The 4th Medical College of Peking University, Beijing, China.
- Department of Rheumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhengjiang, China.
- Department of Orthopaedic Surgery, Yuyao Hospital of Traditional Chinese Medicine, Ningbo, Zhengjiang, China.
- Department of Orthopaedics, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhengjiang, China.
ORCID-Profile: Qiyuan Lu
Zitieren
APA
Chen, M., Lu, L., Mao, Y., Ji, L., Xu, J., Chen, J., Zhu, Y., Yuan, J., Chen, L., Yu, J., & Lu, Q. (2026). Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261477844
Vancouver
Chen M, Lu L, Mao Y, Ji L, Xu J, Chen J, et al. Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261477844
BibTeX
@article{Chen2026,
author = {Chen, Mengmeng and Lu, Lan and Mao, Yujiang and Ji, Lina and Xu, Jianyi and Chen, Junjun and Zhu, Yong and Yuan, Jiandi and Chen, Lei and Yu, Jinsheng and Lu, Qiyuan},
title = {Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2026},
volume = {18},
doi = {10.1177/1759720x261477844}
}
EUVIMED